Arrowhead Pharmaceuticals, Inc. (ARWR)

$22.53

-1.14

(-4.82%)▲

Market is closed - opens 7 PM, 18 Apr 2024

Insights on Arrowhead Pharmaceuticals, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 16.09M → 3.55M (in $), with an average decrease of 77.9% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, 48.67M → -132.86M (in $), with an average decrease of 113.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 72.6%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 311.8%

Performance

  • $22.48
    $23.89
    $22.53
    downward going graph

    0.22%

    Downside

    Day's Volatility :5.9%

    Upside

    5.69%

    downward going graph
  • $20.67
    $42.48
    $22.53
    downward going graph

    8.26%

    Downside

    52 Weeks Volatility :51.34%

    Upside

    46.96%

    downward going graph

Returns

PeriodArrowhead Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-32.06%
-0.7%
0.0%
6 Months
-13.31%
6.6%
0.0%
1 Year
-25.89%
3.7%
-1.5%
3 Years
-66.37%
14.0%
-21.8%

Highlights

Market Capitalization
3.0B
Book Value
$1.49
Earnings Per Share (EPS)
-2.73
PEG Ratio
-1.32
Wall Street Target Price
55.38
Profit Margin
-163.32%
Operating Margin TTM
-3845.26%
Return On Assets TTM
-24.66%
Return On Equity TTM
-106.24%
Revenue TTM
181.7M
Revenue Per Share TTM
1.7
Quarterly Revenue Growth YOY
-94.3%
Gross Profit TTM
240.7M
EBITDA
-285.3M
Diluted Eps TTM
-2.73
Quarterly Earnings Growth YOY
0.1
EPS Estimate Current Year
-2.67
EPS Estimate Next Year
-2.63
EPS Estimate Current Quarter
-0.82
EPS Estimate Next Quarter
-0.39

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 20 Wall street analysts offering stock ratings for Arrowhead Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)
Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
15
Hold
5
5
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 145.81%

Current $22.53
Target $55.38

Company Financials

FY18Y/Y Change
Revenue
16.1M
↓ 48.6%
Net Income
-54.5M
↑ 58.38%
Net Profit Margin
-337.32%
↓ 227.86%
FY19Y/Y Change
Revenue
168.8M
↑ 945.67%
Net Income
68.0M
↓ 224.84%
Net Profit Margin
40.27%
↑ 377.59%
FY20Y/Y Change
Revenue
88.0M
↓ 47.87%
Net Income
-84.6M
↓ 224.39%
Net Profit Margin
-96.09%
↓ 136.36%
FY21Y/Y Change
Revenue
138.3M
↑ 57.16%
Net Income
-140.8M
↑ 66.58%
Net Profit Margin
-101.85%
↓ 5.76%
FY22Y/Y Change
Revenue
243.2M
↑ 75.89%
Net Income
-176.5M
↑ 25.31%
Net Profit Margin
-72.56%
↑ 29.29%
FY23Y/Y Change
Revenue
240.7M
↓ 1.03%
Net Income
-205.3M
↑ 16.31%
Net Profit Margin
-85.27%
↓ 12.71%
Q3 FY22Q/Q Change
Revenue
31.6M
↓ 2.58%
Net Income
-85.9M
↑ 20.73%
Net Profit Margin
-272.18%
↓ 52.56%
Q4 FY22Q/Q Change
Revenue
62.5M
↑ 98.09%
Net Income
-41.8M
↓ 51.35%
Net Profit Margin
-66.85%
↑ 205.33%
Q1 FY23Q/Q Change
Revenue
146.3M
↑ 133.86%
Net Income
48.7M
↓ 216.42%
Net Profit Margin
33.28%
↑ 100.13%
Q2 FY23Q/Q Change
Revenue
15.8M
↓ 89.18%
Net Income
-102.9M
↓ 311.5%
Net Profit Margin
-650.53%
↓ 683.81%
Q3 FY23Q/Q Change
Revenue
16.1M
↑ 1.72%
Net Income
-109.7M
↑ 6.54%
Net Profit Margin
-681.36%
↓ 30.83%
Q4 FY23Q/Q Change
Revenue
3.6M
↓ 77.94%
Net Income
-132.9M
↑ 21.14%
Net Profit Margin
-3.7K%
↓ 3060.23%
FY18Y/Y Change
Total Assets
111.6M
↑ 7.29%
Total Liabilities
16.4M
↓ 29.31%
FY19Y/Y Change
Total Assets
349.8M
↑ 213.45%
Total Liabilities
105.8M
↑ 546.4%
FY20Y/Y Change
Total Assets
522.5M
↑ 49.35%
Total Liabilities
60.7M
↓ 42.61%
FY21Y/Y Change
Total Assets
710.1M
↑ 35.91%
Total Liabilities
301.3M
↑ 396.22%
FY22Y/Y Change
Total Assets
691.9M
↓ 2.56%
Total Liabilities
586.0M
↑ 94.47%
FY23Y/Y Change
Total Assets
765.6M
↑ 10.64%
Total Liabilities
478.4M
↓ 18.36%
Q3 FY22Q/Q Change
Total Assets
691.9M
↓ 7.96%
Total Liabilities
586.0M
↑ 111.08%
Q4 FY22Q/Q Change
Total Assets
891.5M
↑ 28.84%
Total Liabilities
495.1M
↓ 15.51%
Q1 FY23Q/Q Change
Total Assets
891.3M
↓ 0.02%
Total Liabilities
426.2M
↓ 13.92%
Q2 FY23Q/Q Change
Total Assets
795.9M
↓ 10.71%
Total Liabilities
413.9M
↓ 2.89%
Q3 FY23Q/Q Change
Total Assets
765.6M
↓ 3.81%
Total Liabilities
478.4M
↑ 15.59%
Q4 FY23Q/Q Change
Total Assets
626.3M
↓ 18.19%
Total Liabilities
452.6M
↓ 5.4%
FY18Y/Y Change
Operating Cash Flow
-47.2M
↑ 97.27%
Investing Cash Flow
-7.4M
↓ 84.72%
Financing Cash Flow
60.0M
↑ 397.32%
FY19Y/Y Change
Operating Cash Flow
173.0M
↓ 466.42%
Investing Cash Flow
-47.7M
↑ 542.18%
Financing Cash Flow
66.4M
↑ 10.72%
FY20Y/Y Change
Operating Cash Flow
-95.4M
↓ 155.13%
Investing Cash Flow
-240.8M
↑ 404.29%
Financing Cash Flow
257.9M
↑ 288.58%
FY21Y/Y Change
Operating Cash Flow
171.2M
↓ 279.5%
Investing Cash Flow
-141.7M
↓ 41.16%
Financing Cash Flow
11.3M
↓ 95.62%
FY22Y/Y Change
Operating Cash Flow
-136.1M
↓ 179.5%
Investing Cash Flow
-5.4M
↓ 96.18%
Financing Cash Flow
65.2M
↑ 476.61%
FY23Y/Y Change
Operating Cash Flow
-153.9M
↑ 13.05%
Investing Cash Flow
-96.2M
↑ 1675.06%
Financing Cash Flow
253.1M
↑ 288.2%
Q3 FY22Q/Q Change
Operating Cash Flow
-68.7M
↓ 0.26%
Investing Cash Flow
36.4M
↓ 40.53%
Financing Cash Flow
855.0K
↓ 98.59%
Q4 FY22Q/Q Change
Operating Cash Flow
-75.5M
↑ 9.97%
Investing Cash Flow
-80.7M
↓ 321.41%
Financing Cash Flow
250.6M
↑ 29207.13%
Q1 FY23Q/Q Change
Operating Cash Flow
-31.7M
↓ 58.06%
Investing Cash Flow
-36.1M
↓ 55.31%
Financing Cash Flow
520.0K
↓ 99.79%
Q2 FY23Q/Q Change
Operating Cash Flow
-21.4M
↓ 32.29%
Investing Cash Flow
-9.9M
↓ 72.54%
Financing Cash Flow
1.8M
↑ 247.12%
Q3 FY23Q/Q Change
Operating Cash Flow
-25.3M
↑ 17.77%
Investing Cash Flow
30.5M
↓ 408.02%
Financing Cash Flow
152.0K
↓ 91.58%

Technicals Summary

Sell

Neutral

Buy

Arrowhead Pharmaceuticals, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
-19.94%
-13.31%
-25.89%
-66.37%
24.0%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
NA
NA
-1.32
-2.67
-1.06
-0.25
NA
1.49
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
Buy
$3.0B
24.0%
NA
-163.32%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • BlackRock Inc

    10.74%

  • Vanguard Group Inc

    8.61%

  • State Street Corporation

    5.51%

  • FMR Inc

    2.72%

  • JPMorgan Chase & Co

    2.22%

  • Geode Capital Management, LLC

    1.88%

Corporate Announcements

  • Arrowhead Pharmaceuticals, Inc. Earnings

    Arrowhead Pharmaceuticals, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing

Organization
Arrowhead Pharmaceuticals, Inc.
Employees
525
CEO
Dr. Christopher R. Anzalone Ph.D.
Industry
Health Technology

Discover More

FAQs